BRISBANE, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release financial results for the fourth quarter 2018 after the market closes on Wednesday, March 6th, 2019. Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will host a conference call to review the Company’s results beginning at 1:30pm PT/4:30pm ET.
Individuals interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers. Please reference Conference ID: 13687388. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: www.CareDx.com.
A replay of the call with be available beginning March 6th, 2019 at 4:30pm PT/7:30pm ET through 4:30pm PT/7:30pm ET on March 20th, 2019. To access the replay, dial 1-844-512-2921 or 1-412-317-6671 and reference Conference ID: 13687388. The webcast will also be available on CareDx’s website for one year following the completion of the call.
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum, and is the leading provider of genomics-based information for transplant patients.
For more information, please visit: www.CareDx.com.
David Clair, CFA